A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma

Trial Profile

A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2018

At a glance

  • Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 May 2018 Results presented in the GlaxoSmithKline media release.
    • 21 May 2018 According to a GlaxoSmithKline media release, based on the data from this trial GlaxoSmithKline has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) as maintenance treatment of asthma as prophylactic therapy in children aged 5 to 11 years (inclusive).
    • 24 Jul 2017 According to a GlaxoSmithKline media release, based on the data from this trial the company has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) as maintenance treatment of asthma as prophylactic therapy in children aged 5 to 11 years (inclusive).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top